Gene expression levels associated with impaired immune response and increased proliferation could serve as biomarkers for women following cervical cancer screening programmes
Human papilloma virus (HPV) infections vary in their oncogenic potential, and whether an infection progresses to cervical intraepithelial neoplasia (CIN) also depends on the immune response. Therefore, the aim of the present study was to explore biomarkers related to the immune system and cell proliferation, in combination with HPV classified as having high (HOP) or low oncogenic potential (LOP), that can possibly guide a more accurate identification of women following cervical cancer screening programmes in need for immediate follow-up with a biopsy. A next-generation sequencing transcriptomic immune profile analysis applied to 28 persistent CIN3 lesions and 14 normal biopsies identified four genes, the immune markers <i>ARG1</i> and <i>HLA-DQB2</i> and the tumour markers <i>CDKN2A</i> and <i>KRT7</i>, as possible markers for differentiating between CIN3 and normal tissue. To validate these findings, analysis of the relative gene expression of these markers by use of reverse transcriptase real-time quantitative polymerase chain reaction was performed in an independent cohort of 264 (82 normal, 64 CIN1, and 118 CIN2/CIN3) biopsies, and the data were combined with information on the HOP- or LOP-HPV identified in the biopsies. Statistical analysis was performed with receiver operating characteristic curves, reporting area under the curve (AUC) with 95% confidence intervals (CIs), and logistic regression. Statistically significantly higher median expression levels of <i>CDKN2A</i> (<i>p</i> < 0.001) and <i>KRT7</i> (<i>p</i> = 0.045) and significantly lower expression of <i>ARG1</i> (<i>p</i> = 0.012) were found in biopsies with HOP-HPV infections, with no difference detected for <i>HLA-DQB2</i> (<i>p</i> = 0.82). Models using expression levels of <i>CDKN2A</i> (AUC, 0.91; 95% CI, 0.86-0.95), <i>KRT7</i> (0.86, 0.81-0.91), or <i>ARG1</i> (0.78, 0.70-0.85) together with HOP/LOP-HPV class were significantly better than HPV class alone (0.72, 0.66-0.79) in discriminating CIN2/3 versus CIN1 (<i>p</i> < 0.001, <i>p</i> < 0.001, and <i>p</i> = 0.014, respectively).
Authors
- Kristiane Søreng
- Einar Gudlaugsson (ORCID: https://orcid.org/0000-0003-2133-3958)
- Ingvild Dalen (ORCID: https://orcid.org/0000-0002-8160-3211)
- Morten Lapin (ORCID: https://orcid.org/0000-0003-4183-0679)
- Irene Tveiterås Øvestad (ORCID: https://orcid.org/0000-0002-9702-0184)
- Marie Austdal (ORCID: https://orcid.org/0000-0001-7285-103X)
- Saleha Akbari
- Ane Cecilie Munk
- Emiel A. M. Janssen
Institutions
- Stavanger University Hospital (NO)
- Akershus University Hospital (NO)
- Sørlandet Sykehus (NO)
- University of Stavanger (NO)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-12-06
- DOI
- https://doi.org/10.3389/fimmu.2024.1507193
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00